Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
8NJHNR4c3x6gDf3k
Listen
